Scientific Session

Redefining strategic rapid response for high-threat pathogens. Discussions center on global preparedness frameworks and platform technologies designed to achieve the "100-Day Mission" for developing safe and effective vaccines during outbreaks.

Led by infectious disease specialists, this panel demonstrates how clinical evidence drives vaccine innovation. Topics include translating patient-level observations into novel vaccine concepts, enhancing vaccine performance using real-world data, and integrating aimed vaccination strategies into antimicrobial resistance (AMR) management.

This session covers recombinant vaccines, including mRNA, DNA, and viral vector platforms, and specifically highlights the application of Artificial Intelligence in structural biology and antigen discovery (distinct from epidemiological modeling).

This session highlights innovations in vaccine formulation, including next-generation adjuvants that enhance immune response and advanced delivery routes, such as mucosal and transdermal systems, that improve stability and cellular uptake.

Bridging the gap between data and industrial strategy, this session focuses on three core pillars: Molecular Epidemiology for tracking pathogen evolution and variants; AI in Epidemiology to model disease spread using Big Data (distinct from molecular design); and Industrial Translation, emphasizing strategies for effectively moving scientific findings from the laboratory bench to the industrial production line through robust technology transfer.

This session provides a comprehensive overview of the vaccine safety and testing lifecycle, with a particular focus on advanced quality assurance and quality control (QA/QC) enabled by next-generation analytical instrumentation. Key concepts include Quality by Design (QbD), Real-Time Release (RTR), and Process Analytical Technology (PAT), among others.

This panel examines the immunological foundations of vaccines and vaccination. Discussions highlight how immune parameters and effector mechanisms influence vaccine potency, efficacy, and effectiveness, and how these insights translate into clinical innovations.

This panel focuses on the technical processes and infrastructure required for industrial-scale vaccine manufacturing. Discussions will cover management of upstream and downstream production stages, optimization of bioreactor performance, and the design of manufacturing facilities compliant with GMP standards to enable efficient scale-up from pilot to full-scale production.

Moving beyond traditional prophylaxis, this session examines Therapeutic Vaccines. The focus is on immunotherapies for cancer, allergies, autoimmune disorders, and chronic conditions, utilizing vaccine technology for treatment rather than prevention in Communicable and Non-Communicable diseases.

This session focuses on priority diseases in small, large, and companion animals, and examines the economic impact of vaccination programs on livestock productivity and food security. Discussions will also address the design of multi-component vaccines tailored to syndromic disease patterns.

A specialized session on the poultry industry. It addresses the control of major avian viral and bacterial diseases, vaccination schedules for industrial flocks, and ensuring food security through poultry health. As well as designing multiple vaccines specific to syndromes to facilitate vaccination and increase their effectiveness.

Focusing on the business and management side of the industry. Topics include building a robust biotech ecosystem, strategic leadership, forming consortia, and fostering international partnerships for sustainable growth.

Focusing on collaborative economic models to drive growth. This session explores how Public-Private Partnerships (PPPs) can de-risk investment and strengthen the industrial base. Topics include venture capital (VC), blended finance strategies, and the role of government incentives in fostering a competitive vaccine industry.

This panel brings a behavioral-science perspective, focusing on strategies to counter misinformation (infodemics), understand the psychology of vaccine hesitancy, improve risk communication and community engagement (RCCE) to build durable public confidence in vaccination programs.